Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists

  • Sebastien J. Hotte Juravinski Cancer Centre, McMaster University
  • Antonio Finelli Princess Margaret Cancer Centre, University of Toronto
  • Kim N. Chi BC Cancer Agency, University of British Columbia
  • Christina Canil The Ottawa Hospital, University of Ottawa
  • Neil Fleshner Princess Margaret Cancer Centre, University of Toronto
  • Anil Kapoor St. Joseph’s Healthcare, McMaster University
  • Michael Kolinsky Cross Cancer Institute, University of Alberta
  • Shawn Malone The Ottawa Hospital, University of Ottawa,
  • Christopher Morash The Ottawa Hospital, University of Ottawa,
  • Tamim Niazi Jewish General Hospital, McGill University
  • Krista L. Noonan St. Joseph’s Healthcare, McMaster University
  • Michael Ong The Ottawa Hospital, University of Ottawa
  • Frederic Pouliot Centre hospitalier universitaire de Québec, Laval University
  • Bobby Shayegan St. Joseph’s Healthcare, McMaster University
  • Alan I. So Prostate Centre at Vancouver General Hospital, University of British Columbia
  • Delna Sorabji Medical Affairs, Janssen Inc
  • Huong Hew Medical Affairs, Janssen Inc
  • Laura Park-Wyllie Medical Affairs, Janssen Inc
  • Fred Saad Centre Hospitalier de l’Université de Montréal, University of Montreal
Keywords: oncologists, consensus, prostate-specific antigen, surveys and questionnaires, apalutamide

Abstract

Introduction: The Canadian Genitourinary Research Consortium (GURC) conducted a consensus development conference leading to 31 recommendations. Using the GURC consensus development questionnaire, we conducted a survey to measure the corresponding community-based practices on the management of metastatic castration-sensitive prostate cancer (mCSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).

Methods: An 87-item online questionnaire was sent to 600 community urologists and oncologists involved in the treatment of prostate cancer.

Results: Seventy-two community physicians responded to the survey. Of note, 50% community physicians indicated they would treat nmCRPC with agents approved for this indication if advanced imaging showed metastases. Radiation to the prostate for low-volume mCSPC was identified as a treatment practice by 27% of community physicians, and 35% indicated docetaxel as the next line of treatment after use of apalutamide. Use of genetic testing was reported in 36% of community physicians for newly diagnosed metastatic prostate cancer.

Conclusions: There are several areas of community-based management of advanced prostate cancer that could represent potential areas for education, practice tools, and future research.

Published
2020-08-18
How to Cite
Hotte, S. J., Finelli, A., Chi, K. N., Canil, C., Fleshner, N., Kapoor, A., Kolinsky, M., Malone, S., Morash, C., Niazi, T., Noonan, K. L., Ong, M., Pouliot, F., Shayegan, B., So, A. I., Sorabji, D., Hew, H., Park-Wyllie, L., & Saad, F. (2020). Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Canadian Urological Association Journal, 15(2), E90-6. https://doi.org/10.5489/cuaj.6779
Section
Original Research